Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

Study Identifier
TNB383B.9001
CT.gov Identifier
NCT04453397
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Blood Cancer - Multiple Myeloma
    • Study Drug
  • TNB-383B
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Adequate bone marrow function * eGFR ≥ 30 mL/min * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) * Serum calcium (corrected for albumin) at or below the ULN range
    Exclusion Criteria:
    * Candidate for treatment regimens known to provide clinical benefit in MM * Active infection requiring parenteral anti-infective treatment * Any medical or psychiatric condition which in the opinion of the investigator or Teneobio Medical Monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety

    Protocol Summary

    This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.

    Study Locations

    Location
    Status
    Location
    Wake Forest
    Winston-Salem, North Carolina, United States, 27157
    Status
    Not applicable